bs-14278R-A350 [Conjugated Primary Antibody]
DEPDC1B Polyclonal Antibody, ALEXA FLUOR® 350 Conjugated
www.biossusa.com
[email protected]
800.501.7654 [DOMESTIC]
+1.781.569.5821 [INTERNATIONAL]
DATASHEET

Host: Rabbit

Target Protein: DEPDC1B

Immunogen Range: 451-529/529


Clonality: Polyclonal

Isotype: IgG

Entrez Gene: 55789

Swiss Prot: Q8WUY9

Source: KLH conjugated synthetic peptide derived from human DEPDC1B

Purification: Purified by Protein A.

Storage Buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

Storage: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Background:

GTPase activator activity.

Conjugation: ALEXA FLUOR® 350

Excitation/ Emission: 346nm/442nm

Size: 100ul

Concentration: 1ug/ul

Applications: WB(1:300-5000)
IF(IHC-P)(1:50-200)
IF(IHC-F)(1:50-200)
IF(ICC)(1:50-200)

Predicted Molecular Weight: 62


Cross Reactive Species: Human

Predicted Cross Reactive Species: Mouse
Rat
Cow
Rabbit

For research use only. Not intended for diagnostic or therapeutic use.

PRODUCT SPECIFIC PUBLICATIONS
  • Bai, Shoumin, et al. "High levels of DEPDC1B predict shorter biochemical recurrence‑free survival of patients with prostate cancer." Oncology Letters.Read more>>
  • Bai et al. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer. (2017) Oncol.Let. 14:6801-6808Read more>>
  • Ma X et al. High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. (2018) Oncology Letters. 16: 6749-6755Read more>>
  • Ma et al. High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer. (2018) Oncol.Lett. 16:6749-6755Read more>>
  • Z-D Liu. et al. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas. EUR REV MED PHARMACO. 2022 Nov;26(21):7813-7826Read more>>
  • Hairong Fei. et al. DEPDC1B enhances malignant phenotypes of multiple myeloma through upregulating CCNB1 and inhibiting p53 signaling pathway. TISSUE CELL. 2024 Feb;86:102263Read more>>
VALIDATION IMAGES